Abilify Maintena is a long-acting injectable form of aripiprazole, an atypical antipsychotic medication. It is FDA-approved for two conditions in adults: the treatment of schizophrenia and the maintenance treatment of bipolar I disorder. Unlike the daily oral version of aripiprazole, Abilify Maintena is given as a single injection once per month, providing steady medication levels without the need to remember a daily pill.
How It Works in the Brain
Aripiprazole works differently from older antipsychotics. Rather than simply blocking dopamine receptors, it acts as a partial agonist, meaning it can both activate and dampen dopamine signaling depending on what’s happening in the brain at a given moment. When dopamine levels are too high (as in psychosis), aripiprazole partially blocks the receptor and tones down the signal. When dopamine activity is too low, it provides a mild boost. This balancing act is why aripiprazole is sometimes called a “dopamine stabilizer.”
The drug also interacts with serotonin receptors. It partially activates one type of serotonin receptor (which may help with mood and anxiety symptoms) while blocking another type (which is thought to reduce some of the movement-related side effects common with older antipsychotics). This combination of effects across multiple receptor systems accounts for its use in both schizophrenia and bipolar disorder.
What the Injection Looks Like in Practice
Abilify Maintena is always administered by a healthcare provider. You cannot give it to yourself at home. The injection goes into either the upper arm (deltoid muscle) or the buttock (gluteal muscle), and the appointment happens once every month.
The medication comes as a dry powder that gets mixed into a liquid suspension right before injection. It’s available in two strengths: 300 mg and 400 mg. Once injected, the aripiprazole particles dissolve slowly because of their low solubility, which is what creates the extended-release effect. The drug gradually enters your bloodstream over weeks rather than hours.
When you first start Abilify Maintena, you’ll need to continue taking oral aripiprazole for about 14 days after the first injection. This overlap gives the injectable form time to build up to effective levels in your body. After that initial period, the monthly injection maintains those levels on its own.
Who It’s Approved For
The FDA has approved Abilify Maintena for adults only, in two specific situations. The first is schizophrenia treatment. The second is maintenance monotherapy for bipolar I disorder, meaning it’s used on its own to help prevent future mood episodes in people who are already stabilized. It has not been studied in people under 18, and its safety and effectiveness in that age group are unknown.
One important safety note applies to all atypical antipsychotics, including Abilify Maintena: they carry a boxed warning (the FDA’s most serious warning category) about increased risk of death in elderly patients with dementia-related psychosis. The drug is not approved for that use.
Why a Monthly Injection Instead of a Daily Pill
The primary advantage of a long-acting injectable is consistency. In schizophrenia especially, stopping medication is one of the biggest risk factors for relapse. Studies show that among people with stable schizophrenia who stop treatment, roughly 67% will relapse. Antipsychotic treatment at adequate doses can cut that risk by more than half. A monthly injection removes the daily decision of whether to take a pill, which can be particularly helpful for people who struggle with medication routines or who have experienced cycles of stopping and restarting treatment.
Common Side Effects
In a 12-week clinical trial comparing Abilify Maintena to placebo in adults with schizophrenia, the most frequent side effects were:
- Weight gain: 17% of people on the medication versus 7% on placebo
- Akathisia (a feeling of inner restlessness or an inability to sit still): 11% versus 4%
- Injection site pain: 5% versus 1%
- Sedation: 5% versus 1%
- Constipation: 10% versus 7%
Other effects reported by at least 3% to 4% of participants included back pain, joint pain, muscle pain, dizziness, dry mouth, tremor, and upper respiratory infections. Some people (about 4%) actually lost weight during treatment, which is unusual among antipsychotics.
Akathisia deserves special attention because it can feel distressing and is sometimes mistaken for anxiety or worsening psychiatric symptoms. If you experience a persistent urge to move, pace, or shift your weight from foot to foot after starting treatment, that’s worth bringing up at your next appointment. It often improves with dose adjustment or additional medication.
How It Compares to Oral Aripiprazole
The active ingredient is identical. Abilify Maintena and oral aripiprazole (including the brand-name Abilify tablet) deliver the same molecule to the same receptors. The difference is purely in delivery. The injectable version maintains more consistent blood levels because it bypasses the daily peaks and valleys that come with oral dosing. For some people this means fewer side effects tied to those peaks, though the overall side effect profile is similar. The trade-off is monthly visits to a healthcare provider’s office and the discomfort of an intramuscular injection.